Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 16/20 | 0.53 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | STK17B | O94768 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165736 | 0.93 | NPY1R (0.54) | NPY1RMAPKAPK2AOC3 | |
| SCHEMBL504009 | 0.91 | NPY1R (0.45) | NPY1RMAPKAPK2AOC3 | |
| SCHEMBL163374 | 0.89 | NPY1R (0.48) | NPY1R | |
| SCHEMBL164055 | 0.86 | NPY1R (0.48) | NPY1R | |
| SCHEMBL164674 | 0.84 | NPY1R (0.49) | NPY1R | |
| SCHEMBL176185 | 0.83 | NPY1R (0.43) | NPY1R | |
| SCHEMBL504416 | 0.81 | NPY1R (0.46) | NPY1R | |
| SCHEMBL503809 | 0.79 | AOC3 (0.35) | NPY1RMAPKAPK2BRD9BAZ2BAOC3 | |
| SCHEMBL167647 | 0.76 | HTR2C (0.35) | NPY1RMAPKAPK2BRD9BAZ2BAOC3 | |
| SCHEMBL7012282 | 0.75 | HTR2C (0.38) | NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424860-A1 | HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE | MSD K.K. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120028970-A1 | HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE | MSD K.K. (JP) | 2012-02-02 | — | — | US | disclosed |
| WO-2010126163-A1 | HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028970-A1 | HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE | AR, NR5A1, ARL1 | NPY1R 354/4885MAPKAPK2 2901/4885BRD9 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.